COMMUNIQUÉS West-GlobeNewswire
-
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
24/07/2026 -
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
24/07/2026 -
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
24/07/2026 -
MannKind Announces $50 Million Private Placement
24/07/2026 -
ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
24/07/2026 -
Asimov Joins the Genesis Mission, Using Boston University's NSF-Backed Cloud Lab to Power Lab-in-the-Loop AI Models
24/07/2026 -
Persica Pharmaceuticals presents new analyses of microbiology assay sensitivity and intradiscal antibiotic exposure response in chronic Low Back Pain at ASPN 2026 Annual Conference
24/07/2026 -
Treace to Report Second Quarter 2026 Financial Results on August 7, 2026
24/07/2026 -
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
24/07/2026 -
Dyadic Announces Continued Listing on the Nasdaq Capital Market
24/07/2026 -
Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
24/07/2026 -
BiomX Subsidiary Zorronet Expands European Presence Through Two Strategic Collaborations in Europe
24/07/2026 -
Ondra Health Names Every Pharmacy That Fills Its GLP-1 Prescriptions, a Disclosure Most Telehealth Platforms Don't Make
24/07/2026 -
Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
24/07/2026 -
Amwell® to report second quarter 2026 operating results
24/07/2026 -
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
24/07/2026 -
Magnendo Secures $18M Series A Financing to Transform Endovascular Access for Stroke Intervention
24/07/2026 -
Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study
24/07/2026 -
NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease
24/07/2026
Pages